Lung Non-Small Cell Carcinoma — Trials

Lung Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,749
Recruiting: 926
Ph III recruiting: 138
Growth YoY: +3.1%
Industry share: 44%
Top sponsor: AstraZeneca
Termination share: 39%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,044)

clinicaltrialsPublishedShowing 101–150 of 298 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04853342	To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy(FORWARD)	recruiting	Phase 3	318	Allist Pharmaceuticals, Inc.INDUSTRY	1	Aug 13, 2026	clinicaltrials
NCT05671510	ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors(PRESERVE-003)	active not recruiting	Phase 3	630	OncoC4, Inc.